Last reviewed · How we verify
NCT04140448: UWFA-RVO-ME
Ultra-wide-field Fluorescein Angiography in Patients With Macular Edema Secondary to Retinal Vein Occlusion
trial testing Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS] in Retinal Vein Occlusion in 60 participants. Status unknown.
30 October 2024
Quick facts
| Lead sponsor | Renmin Hospital of Wuhan University |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 60 |
| Start date | 9 October 2023 |
| Primary completion | 30 October 2024 |
| Estimated completion | 15 December 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS] — full drug profile →
- Ultra-wide Fluorescein Angiography
Conditions studied
- Retinal Vein Occlusion — all drugs for Retinal Vein Occlusion →
- Macular Edema — all drugs for Macular Edema →
Sponsor
Renmin Hospital of Wuhan University
Who can join
18 and older, any sex, with Retinal Vein Occlusion or Macular Edema. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study mainly observed the ischemic index and vascular leakage index changes on ultra-wide field fluorescence angiography after anti-VEGF treatment , and whether these changes correlated with treatment efficacy in patients with macular edema secondary to retinal vein occlusion.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04140448
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Ranibizumab 0.5 MG/0.05 ML Intraocular Solution [LUCENTIS]
Trials testing the same drug.
- NCT04387604 — Effect of the Vitreous in Response to Intravitreal Injections of Ranibizumab for the Treatment of Diabetic Macular Edema · completed
- NCT04018833 — Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema · completed
Other recruiting trials for Retinal Vein Occlusion
Currently open trials in the same condition.
- NCT07002372 — Effect of Video Viewing on Intravitreal Injection Experience · NA · recruiting
- NCT06439576 — Real World Evidence in China: Faricimab Use in Diabetic Macular Edema, Retinal Vein Occlusion, and Neovascular Age-Relat · recruiting
- NCT07106268 — Aqueous Humor Proteome in Retinal Vein Occlusion With Macular Edema · active not recruiting
- NCT05476926 — A Real-World Study to Gain Clinical Insights Into Roche Ophthalmology Products · active not recruiting
- NCT04505618 — Optical Coherence Tomography Angiography in Subjects With Retinal Vascular Disease · NA · recruiting
Other Renmin Hospital of Wuhan University trials
Trials by the same sponsor.
- NCT07587294 — Efficacy and Safety of Ultrasound Modulation of Stellate Ganglion for the Prevention of Ventricular Arrhythmia in Patien · NA · not yet recruiting
- NCT07269509 — Evaluation of the Efficacy and Safety of an Intensified Strategy of Intratonsillar Immunotherapy (ITIT) for Allergic Rhi · NA · not yet recruiting
- NCT07151560 — Efficacy and Safety of Two Bladder-preserving Treatment Durations With Disitamab Vedotin Plus Toripalimab Combination in · Phase 2 · not yet recruiting
- NCT07085221 — Digital Out-of-hospital Management on Clinical Outcomes in Patients With Early Cardiogenic Shock · NA · recruiting
- NCT06614985 — The Efficacy and Safety of Treatment With Telitacicept in Primary Membranous Nephropathy · Phase 2 · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04140448 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Renmin Hospital of Wuhan University
- Last refreshed: 18 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04140448.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing